Biomedical Engineering Reference
In-Depth Information
KEREIAKES DJ, COX DA, HERMILLER JB, MIDEI MG, BACHINSKY WB, NUKTA ED, LEON MB,
FI NK S, MARIN L and LANSKY AJ. Guidant multi-link vision stent registry investiga-
tors: usefulness of a coronary stent alloy.
Am J Cardiol
2003;
92
: 463-466.
KLOMP M, BEIJK MAM and DE WINTER RJ. Genous (TM) endothelial progenitor cell-
capturing stent system: a novel stent technology.
Expert Rev Med Devices
2009;
6
(4): 365-375.
KOCIJAN A and MILOSEV I. The infl uence of complexing agent and proteins on the
corrosion of stainless steels and their metal components.
J Mater Sci: Mater Med
2003;
14
: 67-77.
KOLLUM M, FARB A, SCHREIBER R, TERFERA K, ARAB A, GEIST A, HABERSTROH J, WNENDT
S, VIRMANI R and HEHRLEIN C. Particle debris from a nanoporous stent coating
obscures potential antiproliferative effects of tacrolimus-eluting stents in a
porcine model of restenosis.
Catheter Cardiovasc Interv
2005;
64
: 85-90.
KOSTER R, VIELUF D, KIEHN M, SOMMERAUER M, KAHLER J, BALDUS S, MEINERTZ T and
HAMM CW. Nickel and molybdenum contact allergies in patients with coronary
in-stent restenosis.
Lancet
2000;
356
: 1895-1897.
KRUCOFF MW, KEREIAKES D, PETERSON JL,
et al.
A novel bioresorbable polymer pacli-
taxel-eluting stent for the treatment of single and multi-vessel coronary disease
primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative
for Restenosis) II study.
J Am Coll Cardiol
2008;
51
: 1543-1552.
KUTRYK M, SERRUYS S and DUNITZ M. Coronary stenting: current perspectives. In:
A
Companion to the Handbook of Coronary Stents
, 1999, Martin Dunitz.
KUTRYK MJB, KULISZEWSKI MA, JAFFE R, TIO FO, JANICKI C, SWEET WL, SPARKES JD and
STRAUSS BH. Low energy
-emitting stents inhibit intimal hyperplasia with minimal
'edge effects” in pig coronary artery model.
Cardiovasc Revascularisation Med
2007;
8
: 28-37.
LAGERQVIST B, JAMES SK, STENESTRAND U, LINDBACK J, NILSSON T and WALLENTIN L.
Long term outcomes with drug eluting stents versus bare metal stents in Sweden.
N Eng J Med
2007;
356
: 1009-1019.
LANGENHOVE GV, KUTRYK M and SERRUYS Y. Pharmacological adjuncts to coronary
stenting: the case of stent thrombosis.
J Am Coll Card
1996;
27
: 494-503.
LAQUERRIERE P, GRANJEAN-LAQUERRIERE A, JALLOT E, BALOSSIER G, FRAYSSINET P and
GUENOUNOU M. Importance of hydroxyapatite particles characteristics on cytokine
production by human monocytes
in vitro
.
Biomaterials
2003;
24
: 2739-2747.
LAU KW and SIGWART U. Intracoronary stents.
Indian Heart J
1991;
43
(3), 127-139.
LAU K, MAK K, HUNG J and SIGWART U. Clinical impact of stent construction and design
in percutaneous coronary intervention.
Am Heart J
2004;
147
(5): 764-773.
LEE CW, CHAE JK, LIM HY, HONG MK, KIM JJ, PARK SW and PARK SJ. Prospective random-
ized trial of corticosteroids for the prevention of restenosis after intracoronary
stent implantation.
Am Heart J
1999;
138
: 60-83.
LEMONS J. Ceramics: past, present and future.
Bone
1996;
19
: 121s-128s.
LEMOS PA, MOULIN B, PERIN MA, OLIVEIRA LARR
et al.
Randomised evaluation of two
drug-eluting stents with identical metallic platform and biodegradable polymer
but different agents (paclitaxel or sirolimus) compared against bare stents: 1-year
results of the PAINT trial.
Coronary Artery Disease
2009 (published online 9 June
2009).
LEVY Y, MANDLER D, WEINBERGER J, DOMB AJ. Evaluation of drug eluting stents' coating
durability - clinical and regulatory implications.
J Biomed Mat Res Part B: Appl
Biomater
2009 (Published online 1 June 2009).
γ
Search WWH ::
Custom Search